Search clinical trials for: rAvPAL-PEG 0.01 mg/kg

Total 1244 results

BioMarin Pharmaceutical

Completed

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

Phenylketonuria

United States
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States
Integro Theranostics

Recruiting

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Breast Cancer | DCIS | Invasive Duct Carcinoma of Breast

United States
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of
NuvOx LLC
University of Arkansas

Completed

A Phase Ib/II in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
Bracco Diagnostics, Inc

Completed

Crossover Comparison of MultiHance and Dotarem (BENEFIT)

Brain Disease

United States
Pfizer

Completed

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Carcinoma, Breast

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
Guerbet

Completed

Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis

Chronic Liver Disease | HepatoCellular Carcinoma

France
Viridian Therapeutics, Inc.

Not yet recruiting

A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

Thyroid Eye Disease

United States
BioMarin Pharmaceutical

Completed

Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria

Phenylketonuria

United States
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Shire

Completed

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

Short Bowel Syndrome

United States, Denmark, France, Canada, Belgium, Netherlands, Poland, United Kingdom
BioMarin Pharmaceutical

Completed

Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

Phenylketonuria

United States
BioMarin Pharmaceutical

Completed

Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU

Phenylketonuria (PKU)

United States
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Shire

Completed

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

Short Bowel Syndrome

United States, France, Germany, Canada, Netherlands, Poland, Denmark, Belgium, United Kingdom
Yong-Hee Park
Chung-Ang University

Completed

Optimal Dose of Intravenous Oxycodone for Endotracheal Intubation

Blood Pressure | Intubation Complication

Korea, Republic of
Bayer

Completed

A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants

Healthy Volunteers | Contrast Enhancement in Magnetic Resonance Imaging

China
University of Reading

Completed

An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men

Vasodilation

United Kingdom
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Alzheimer's Disease

United States, Germany, Canada, Austria
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

Alzheimer's Disease

United States
Seoul National University Hospital

Withdrawn

Optimal Dose of i.v Oxycodone for Postoperative Pain After Laparoscopic Colorectal Surgery

Pain

Korea, Republic of
QED Therapeutics, Inc.

Recruiting

Study of Infigratinib in Children With Achondroplasia

Achondroplasia

United States, Spain, United Kingdom, France, Canada, Australia
Seoul National University Hospital

Completed

Optimal Dose of i.v Oxycodone for Postoperative Pain

Pain

Korea, Republic of
NeuroActiva, Inc.

Unknown

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 (NEUROSIVIR)

Severe Acute Respiratory Syndrome | Covid19 | Corona Virus Infection | Severe Acute Respiratory Syndrome (SARS) Pneumonia | Neurodegeneration | Neuroinflammatory Response | Severe Acute Respiratory Infection | Severe Acute Respiratory Syndrome of Upper Respiratory Tract

United States
Cardiox Corporation

Withdrawn

Cardiox Liver Function Test Pivotal Trial (LFT-0002)

Liver Failure | Hepatic Failure

United States
Pfizer

Terminated

A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

Alzheimer Disease

Australia, France, Finland, Portugal, Spain, United Kingdom, Poland, Japan, Italy, Belgium, Switzerland, Netherlands, Chile, Slovakia, Sweden, New Zealand, South Africa
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma

Melanoma

United States
Bayer

Completed

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Brain Diseases | Spinal Cord Diseases

United States, Colombia, Argentina, Brazil
Pfizer

Terminated

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Alzheimer Disease

United States, Spain, France, Japan, New Zealand, Belgium, Portugal, Netherlands, Argentina, United Kingdom, Australia, Slovakia, Poland, Chile, Finland, Italy, South Africa, Sweden, Switzerland
Viridian Therapeutics, Inc.

Recruiting

A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)

Thyroid Eye Disease

United States, Turkey
Tunitas Therapeutics, Inc.
Tunitas Therapeutics Australia Pty Ltd

Terminated

Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

Allergy and Immunology

Australia
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC

Terminated

An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

Colitis, Ulcerative

United States, Poland, Germany, France, India, Romania, Serbia, Ukraine, Israel, Canada, Netherlands, Sweden, New Zealand, Russian Federation, Australia, Belgium, Hungary, Bulgaria, Slovakia, Latvia, Lithuania, Austria
MedImmune LLC
AstraZeneca

Terminated

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Mexico, Peru, South Africa, Canada
Joben Bio-Medical Co., Ltd.
Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General... and other collaborators

Unknown

Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients

Radiodermatitis

Taiwan
University of California, San Francisco
Bill and Melinda Gates Foundation; Wellcome Trust; Malaria Research and Training... and other collaborators

Completed

Phase2a Primaquine Dose Escalation Study

Malaria

Mali
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
Merck Sharp & Dohme LLC

Completed

Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)

Anesthesia
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

Influenza

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

Influenza

United States
Providence Health & Services

Completed

α-TEA in Advanced Cancer

Metastatic Sarcoma | Metastatic Carcinoma | Metastatic Lymphoma

United States
Healthgen Biotechnology Corp.

Completed

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Ascites Hepatic

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
ViGenCell Inc.

Not yet recruiting

A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)

Graft Versus Host Disease

Search clinical trials for: rAvPAL-PEG 0.01 mg/kg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations